Applying integrated and efficient translational science to develop new treatments that help combat and cure diseases.
Bringing transformational treatments to patients sooner
Brim Biotechnology, Inc. (6885), founded in 2013, is a new drug development company that applies an innovative translational science–driven R&D model to create novel therapies aimed at combating and curing diseases. With extensive drug development experience, Brim’s professional team identifies innovative opportunities from both domestic and international sources. Through co-development and technology in-licensing, the Company integrates collaborative strengths to drive drug development forward, and further engages optimal CRO and CMO partners to advance its products to the Proof-of-Concept (PoC) stage.
After achieving PoC, Brim adopts a licensing or strategic partnership approach to transfer projects to the most capable development teams for late-stage clinical trials and eventual commercialization.Brim’s key development programs include BRM421 for dry eye disease, BRM424 for neurotrophic keratitis, BRM521 for osteoarthritis, BRM411 for glaucoma, and BRM412 for neovascular ocular diseases.
In addition, Brim is actively expanding into the field of precision medicine. The Company acquired a 42% equity stake in Compass Bioinformatics through a cash capital injection to explore combination therapy development. This move demonstrates Brim’s dual-engine growth strategy in innovative drug development and precision medicine.
Our Pipeline
Our extensive experience and unique drug development engine enable us to identify and incubate high-potential novel drug candidates and rapidly deliver partner-ready clinical assets. Our lead platform is our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP), which can be applied across multiple therapy areas and indications. PDSP is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. This platform opens up exciting possibilities for wound healing and tissue regeneration due to its ability to enhance cell proliferation and differentiation.
Worldwide license for developing PDSP
In 2015, BRIM was granted an exclusive, worldwide license for developing PDSP in all therapeutic indications including dry eye disease, corneal wound healing, diabetic ulcer wound healing, osteoarthritis, androgenic alopecia, and muscle/tendon regeneration.
Our lead assets
Our lead asset, BRM421, is on track to become a first-in-class treatment for dry eye disease (DED) which treats and repairs cornea damage. BRM421 has demonstrated safety and efficacy in two clinical studies. BRIM is devoted to expanding this synthetic peptide’s indications, including treatments for neurotrophic keratitis (BRM424), and osteoarthritis (BRM521).
Award
2024International Innovation Award (IIA)
Enterprise Asia International Innovation Award
2020Taipei Biotech Awards
Innovative Technology Award – Gold Prize
2020Taiwan BIO Awards
Outstanding Company of the Year
2019National Innovation Award
National Innovation Award
More
